Drug
Milvexian
Milvexian: highest development phase Phase 3, developed by Johnson & Johnson. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| Milvexian NCT05757869 | Phase 3 | Atrial Fibrillation |
| Milvexian NCT05706753 | Phase 1 | Healthy Female |
Latest
No recent events.
Follow Milvexian on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.